Glofitamab in Refractory or Relapsed Diffuse Large B Cell Lymphoma after Failing CAR-T Cell Therapy: A Phase II LYSA Study

Investigators enrolled patients wwith diffuse large B cell lymphoma refractory or in first progression/relapsed after CAR-T cell therapy in a Phase II single-arm, nonblinded trial to evaluate the efficacy and safety of glofitamab.